Current and emerging treatment strategies for hair loss in women of color

U.R. Okereke, MD, MSCI a, A. Simmons, MD b, V.D. Callender, MD c,d,\textsuperscript{*}

\textsuperscript{a} University of Iowa Clinics and Hospitals, Iowa City, Iowa
\textsuperscript{b} University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, Ohio
\textsuperscript{c} Howard University College of Medicine, Washington, District of Columbia
\textsuperscript{d} Callender Dermatology & Cosmetic Center, Glenn Dale, Maryland

\textbf{Abstract}

Hair loss is common in women of color, and is associated with significant psychosocial complaints. Early clinical recognition and prompt initiation of intervention with medical treatment is critical to halt the disease process. In this article, we review the clinical presentations of nonscarring and scarring alopecias in women of color, use of dermoscopy for early recognition of the disease process, and medical, procedural, and surgical interventions. In conditions that result in scarring alopecia, such as late-stage traction, frontal fibrosing, or central centrifugal cicatricial alopecia, patients may benefit from procedural interventions, such as hair transplantation, platelet rich plasma injections, low-level laser therapy, or scalp therapy.

© 2018 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

\textbf{Introduction}

Alopecia is a disease of the pilosebaceous unit, secondary to an underlying condition that may lead to scarring or nonscarring hair loss. The development of alopecia is common among women, and increases with age. Studies have shown its profound effect on the psychosocial aspects of a woman’s life (Callender et al., 2004). The negative psychological effects of alopecia are more profound in women than in men, and affect younger women to a greater extent (Davis and Callender, 2018).

Narrowing down the correct diagnosis will guide management plans, patient expectations, and treatment outcomes. Mubki et al. (2014) delineated an approach to hair loss that that includes obtaining a history of hair loss, hair examination, the use of trichoscopy, laboratory evaluations, and scalp biopsy. Regardless of the etiology, early diagnosis and medical treatment are vital to preventing further hair loss. When these conditions become end stage, hair transplantation may be an option to restore cosmosis. In this paper, we cover the types of alopecia that affect women of color, focusing on medical, surgical, and alternative treatment strategies.

\textbf{Alopecias}

\textbf{Nonscarring alopecias}

Female pattern hair loss (FPHL) is most common in postmenopausal women (Fig. 1). The cause is multifactorial, with genetics and androgens both playing a major role. First-line medical therapy includes topical minoxidil 2% or 5%, which are both available in foam or solution over the counter. For women of color with thermally straightened (temporary) hair, this may be compounded into an ointment or oil to prevent the hair from reverting to the patient’s natural curl pattern (Callender et al., 2004). Second-line medical treatments include antiandrogen agents, such as spironolactone 100 mg to 200 mg, finasteride 1 mg to 5 mg/day, and dutasteride 0.5 mg/day. Increased incidence of adverse effects, such as decreased libido, irregular menstruation, breast tenderness, dry skin, mild acne, headache, dizziness, and increased body hair, were dose-dependent and reported in patients on finasteride 5 mg/day (Dinh and Sinclair, 2007; Hirshburg et al., 2016; Kohler et al., 2007; Oliveira-Soares et al., 2013; Yeon et al., 2011). To prevent teratogenic effects, finasteride...
and dutasteride should only be prescribed to women who cannot or do not want to become pregnant.

In a recent observational pilot study of 100 women, once daily oral minoxidil 0.25 mg and oral spironolactone 25 mg resulted in a reduction in hair loss severity scores and shedding (Sinclair, 2018). The mean change in blood pressure was -4.52 mmHg systolic and -6.48 mmHg diastolic. Side effects were seen in eight women (8%), were generally mild, and included urticaria (2 cases), postural hypotension (2 cases), and facial hypertriglyceridemia (4 cases). No patients developed hyperkalemia or other blood test abnormalities. Six women continued treatment, and the women who developed urticaria did not discontinue treatment.

Acquired trichorrhexis nodosa (ATN) is characterized by loss of the hair shaft cuticle, leading to fragility and breakage (Lawson et al., 2017; Taylor et al., 2017; Fig. 3). The prevalence of ATN is unknown. Causative factors include dry/brittle hair, trauma secondary to grooming and styling practices (e.g., excessive brushing, tight braiding, heat/chemical straightening, and color processing), scratching secondary to seborrheic dermatitis, and underlying medical conditions (e.g., iron deficiency and hypothyroidism).

Treatment options are based on the cause, which may be multifactorial. Discontinuing traumatic hairstyling/grooming or at least refraining from these practices for 6 to 12 months is recommended, along with a daily hair-moisturizing routine with a silicone-based product. During this time, wearing the hair in its natural state or a protective style is encouraged. Examples of protective styles include loosely braided hair alone or with sewn-in weaves or wigs (Taylor et al., 2017). The use of sewn-in weaves for ATN is controversial due to the ability of the wefted weave hair and the tight braids to which the wefted weave hair is attached to cause TA. Sewn-in weaves are also associated with central centrifugal cicatricial alopecia (CCCA; Gathers et al., 2009). Thus, they should be used with caution, and dermatologists should educate patients on early clinical symptoms of TA and appropriate grooming practices when wearing sewn-in weaves.

**Scarring alopecias**

CCCA is a common and progressive form of lymphocyte predominant scarring alopecia that starts at the crown or vertex scalp, and spreads in a peripheral or centrifugal pattern (Dlova et al., 2017; Fig. 4). Along with the clinical observation of hair loss, there may be subclinical inflammation based on biopsy test results of a normal-appearing scalp (Bolduc et al., 2016). The condition commonly affects women of African descent, with the incidence in African-American women reportedly higher (5.6% and 16.2%) than in African women (2.7%; Kyei et al., 2011; Olsen et al., 2011).

Study results regarding the relationship between dermatitis and bacterial folliculitis and the development of CCCA are in conflict. One study found a possible link between diabetes mellitus type 2 and CCCA (Kyei et al., 2011), and more recently, an association with uterine leiomyomas has been suggested (Dina et al., 2018). A genetic linkage with CCCA has been proposed with an autosomal dominant inheritance with partial penetrance (Dlova et al., 2014). There is a range of signs and symptoms associated with CCCA, including the presence of hair breakage (Callender et al., 2012), papules, pustules, tenderness or pruritus of the scalp, or no symptoms at all (Lawson et al., 2017). Key findings on dermoscopy include perihilar white/grey halo, erythema, and the presence of scale (Fig. 5; Miteva and Tosti, 2014). The perihilar white/grey halo corresponds on pathology to the lamellar fibrosis that surround the outer root sheath.

In the active phase of the disease, first-line treatment includes high-potency topical corticosteroid agents, intralesional corticosteroid agents, calcineurin inhibitors, and oral doxycycline or minocycline for the anti-inflammatory effects. Hydroxychloroquine may also be used to decrease inflammation (Lawson et al., 2015, 2017). Once the disease has stabilized, maintenance is achieved with mid-potency topical corticosteroid agents and/or calcineurin inhibitors. Disease must be quiescent on medical therapy for 9 to 12 months, and confirmed with a test biopsy before hair transplantation can be considered (Lawson et al., 2017).
Frontal fibrosing alopecia (FFA) is a variant of lichen planopilaris that affects the frontoparietal hairline, and often the eyebrows (Fig. 6; Kossard, 1994). The etiology of FFA is unknown, and a possible environmental association with the use of leave-on facial skincare products and sunscreen lotions remains controversial (Aldoori et al., 2016; Dhana et al., 2017). Follicular hyperkeratosis and perifollicular erythema may also be seen. The clinical presentation of FFA in women of color and Caucasian woman varies. Table 1 highlights these differences.

FFA is reported to commonly affect postmenopausal women, but a review of FFA cases showed that the average age at the time of diagnosis in patients of African descent was 40 to 42 years old, with varying data noting 39% and 65% to 75% of patients presenting in premenopausal age ranges (Callender et al., 2016; Lawson et al., 2017). The slow progression of the disease may lead to difficulty specifying the age of onset, and present treatment challenges due to the presence of scarring at the time of diagnosis. Identifying clinical correlations may help with the diagnosis of FFA. In 2016, Aldoori et al. (2016) found an association with the use of sunscreen lotion in patients with FFA. The authors found that women with FFA patch tested positive to fragrances more frequently, and had higher rates of thyroid disease compared with women without FFA.

Reports in the literature have also demonstrated a likely positive correlation between FFA and lichen planus pigmentosus (LPPigm), with some suggesting that LPPigm may be a herald sign of FFA in patients of African descent (Dlova, 2013). In a case report of seven African-American women with FFA and LPPigm, the findings supported the theory that FFA and LPPigm likely exist on the same disease spectrum (Uwakwe et al., 2018). McMichael et al. (2003) postulate that FFA patients with darker skin types may be more likely to develop LPPigm.

First-line treatments for both conditions include topical and intralesional steroidal agents to decrease inflammation that affects the hair follicles. Oral therapies include doxycycline, minocycline, or hydroxychloroquine for their anti-inflammation effects, and immunosuppressant treatments such a cyclosporine or mycophenolate mofetil. Five-alpha reductase inhibitors such as finasteride and dutasteride have been shown to slow the progression of FFA (Taylor et al., 2017; Uwakwe et al., 2018). Table 2 summarizes the most common forms of nonscarring and scarring alopecias in women of color.

Hair restoration: Surgical and procedural approach

According to the 2017 International Society of Hair Restoration Surgery (ISHRS) practice census results, 597,181 patient hair transplant surgeries were performed worldwide. On average, 85.7% of patients were men and 14.3% were women (ISHRS, 2017). No data are available on the ethnic breakdown of patients seeking hair transplant surgery, but the changing demographics of the United States serve as an indication that more persons with Afro-textured hair will present for surgical treatment of hair loss. As awareness of the epidemic of alopecia in patients with skin of color increases, so will the requests for hair transplantation in this population. Thus, recognizing the differences in hair morphology in patients with Afro-textured hair and its impact on surgical instrumentation and technique in hair transplant surgery is critical.

We examined different methods for hair restoration, including transplantation, platelet-rich plasma (PRP) injection, low-level laser therapy, and scalp micropigmentation. In many cases, a combination of techniques may provide the best cosmetic result for the patient.

Hair transplantation

Hair transplantation is an effective surgical treatment for women of color with FPHL, TA, and may also be considered in patients with
stable CCCA as determined by clinical and histologic evaluations. Options for a surgical intervention include scalp reduction, flap rotations, follicular unit transplantation (FUT), and follicular unit extraction (FUE; Callender and Davis, 2013; Rassman et al., 2002). The ISHRS reports that in 2016, FUE was the most common method of donor harvesting (52.6%).

Performing these procedures in patients with afro-textured hair is challenging, and steed to avoid transection of the hair follicle within the graft requires exceptional attention and expertise (Callender and Davis, 2013; Singh and Avram, 2013; Umar, 2016). FUE has advantages and disadvantages and, thus, requires an individualized approach depending on the severity of the hair loss, flexibility of the scalp, and shape of the hair.

Generally, patients of African descent tend to have sprial or helical hair structures that appear clinically as tightly coiled, but there is considerable individual variation among Africans and African Americans (McMichael, 2003; Westgate et al., 2017). Additionally, patients with skin of color have a lower average hair density than whites; however, the curly morphology of the hair follicle, slightly higher number of hair groupings in each follicular unit, and less contrast between the scalp skin color and hair color may all work together to create the appearance of fullness and more coverage after hair transplantation (Callender, 2006; Pierce, 1976). The key four steps to perform a hair transplantation procedure include donor harvesting, graft preparation, recipient-site creation, and graft placement (Callender, 2016).

### Table 1

| Clinical presentation | Women of African descent | Caucasian women |
|-----------------------|--------------------------|-----------------|
| Average age at diagnosis, years | 40-42<sup>1</sup> | 55.5-63<sup>1</sup> |
| Frontotemporal hair loss | + | + |
| Follicular hyperkeratosis | + | + |
| Scalp pruritus | +/- | + |
| Eyebrow alopecia | + | + |
| Perifollicular erythema<sup>1</sup> | +/- | + |
| Speckled follicular hyperpigmentation on dermoscopy<sup>1</sup> | + | - |
| Scale<sup>1</sup> | +/- | + |
| Loss of follicular ostia | + | + |
| Papules/pustules<sup>2</sup> | +/- | +/– |
| Lichen planus pigmentosus (LPPigm) | + | – |

<sup>1</sup> Symptoms may not be present in women of color at the time of diagnosis because they may not be as common or as noticeable due to increased pigment in the skin (Callender et al., 2016).

<sup>2</sup> Sources: Callender et al., 2016; Samrao et al., 2010.

#### Donor harvesting

The types of donor harvesting include donor ellipse for FUT and punch technique for FUE. Donor ellipse for FUT involves excising a single strip of donor tissue from the occipital scalp in a manner that limits the transection of hair follicles, and results in a less visible scar. FUE is a modern technique for hair transplantation that utilizes small punch excisions (≤1 mm) to extract follicular units from the donor site to produce a barely perceptible (undetectable) scar (Rassman et al., 2002). FUE can be performed manually using non-motorized handheld punches or with punches mounted on a motorized, handheld piece (i.e., Neograft, https://neograft.com; Smartgraft, http://smartgraft.com).

Critics propose that, while FUE results in decreased scarring, complications include a higher rate of transection and increased time required to harvest follicular units (Callender and Davis, 2013; Harris, 2013). Singh and Avram (2013) have suggested methods to improve the transection rate of conventional FUE in Afro-textured hair, including limiting the depth of the initial score incision and increasing the punch size to a diameter that is large enough to encompass the amplitude of the subcutaneous curl wave of the follicle (greater than the diameter of the C-curve of the follicle; Fig. 7; Singh and Avram, 2013).

Umar reports that limiting the depth of the initial score increases the effort required to separate the remaining tissue attachments of the follicle, inducing more trauma to the grafts and significantly increasing surgery time (Umar, 2016). In addition, increasing punch sizes to accommodate the subcutaneous amplitude of the curl wave of the grafts can result in unacceptably large punch sizes (≥3-4 mm in some patients) with the risk of unacceptable scarring sequelae. Data from Umar’s retrospective case series of 18 patients with tightly curled Afro-textured hair suggests that a curved nonrotary punch can be reliably used. This is a one-step FUE method that involves the complete separation of the follicle from its attachments in single-cutting action, with minimal need for further dissection, reducing additional trauma to the grafts (Fig. 8; Umar, 2016). The transection rate was <10%. This is the first evidence for eliminating the consideration of punch size as the cause for the difference in performance and transection rates.

Subsequently, Umar (2016) demonstrated that small textured and flared rotary punches that have been designed to minimize im-paction (Intelligent Punches) are self-navigating and successful in extracting Afro-textured hair FUE, with lower transection rates than the 10% observed with the nonrotatory device (Fig. 8). Depth control is irrelevant with this device. The extraction process is further enhanced by a hydrating system that delivers physiologic fluid to the punch tip to lubricate and augment its ability to glide through the course of the hair curvature (Dr.UGraft, https://ugraft.com). With this, Umar (2016) demonstrated that both the nonrotatory and rotary punch are capable of performing FUE in Afro-textured hair with a transection rate <10%.

Trichophytic closure is a technique used to minimize scars by trimming the epidermis of one edge of the wound before suturing the wound margins together (Rassman et al., 2002). Undermining the wound margins, which results in less tension, and limiting the width to <1 cm, also aid in minimizing the size of the donor scar (Taylor et al., 2016).

#### Graft preparation

During graft preparation, the donor strip from FUT is converted into individual grafts of different sizes (Rogers and Callender, 2014). Caution must be taken with curly hair to avoid transection of the hair follicle. A bendable blade, such as a DermaBlade, is often used to complement the curvature of the hair, and is very useful in the...
dissection of individual follicular units, particularly in patients with curved hair follicles (Fig. 9; Callender, 2011). Due to its flexibility, the curved blade decreases the transection rate of the hair follicle and the necessity for multiple cuts. The grafts that contain one to four follicular units are created, and set in saline for insertion into the recipient site. Of note, dissection of individual follicular units is eliminated with FUE.

Recipient site creation and graft placement

A number of surgical instruments can be used to create recipient sites in areas of hair loss. The selection of instrumentation is based on the degree of the curl of the hair, with sites that range from 1.2 mm to 2.0 mm in size in patients with significant curl patterns (Callender et al., 2004; Rogers and Callender, 2014).

Robotic methods for hair transplantation

Robotic methods for FUE were created and approved for use by the U.S. Food and Drug Administration. When physician-controlled, this computer-assisted device facilitates standardized, reproducible extraction of follicular units from donor sites that is safe, effective, and less operator dependent (Rashid, 2014; Rose and Nusbaum, 2014). Presently, the only robotic system is Artas (https://artas.com). This device should be used with caution in patients with Afro-textured hair due to an increase risk of transection.

Table 2
Most common types of alopecia in women of color

| Conditions   | Epidemiology                                                                 | Etiology                                                                 | Location                                      | Medical treatments                                                                                      | Treatment pearls                                                                                     |
|-------------|-------------------------------------------------------------------------------|--------------------------------------------------------------------------|-----------------------------------------------|--------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|
| Nonscarring | FPHL Prevalence unknown in women of African descent                             | Multifactorial; hereditary and androgenetic                               | Thinning of crown and frontal scalp with frontal hairline preserved | Topical minoxidil 2-5% solution or foam; spironolactone; finasteride                                 | Combination therapy: PRP + HT + minoxidil (alternative vehicle formulation)                            |
|             | TA No prevalence data for United States 37.1% of African women in Capetown, South Africa (Khumalo and Nagwanya, 2007) | Follicular trauma secondary to hairstyles prone to traction               | Discontinue hairstyles leading to traction; avoid chemical processing; topical/oral antibiotic treatments for folliculitis; topical/intralesional steroid agents; topical 2-5% minoxidil | HT; PRP; counseling parents on appropriate hairstyles for children that reduce traction                 |
|             | ATN Prevalence unknown                                                         | Loss of cuticle along hair shaft due to hair styling, grooming, and processing; secondary to CCCA; trauma/scratching due to seborrheic dermatitis; nutritional deficiencies; thyroid disease | Hair shaft                                    | Correction of underlying medical condition(s); discontinue causative styling practices; use of protective hairstyles | HT; PRP; counseling parents on appropriate hairstyles for children that reduce traction                 |
|             | Scarring                                                                       | Unknown – multifactorial; proposed link between diabetes mellitus type 2; possible AD inheritance | Crown/vertex scalp with peripheral/centrifugal spreading | Topical/intralesional steroid treatments; doxycycline or minocycline; hydroxychloroquine | Can coexist with FPHL; may consider HT if stable on medical treatment for 1 year                     |
|             | CCA True prevalence unknown; may vary between 5.6%-16.2% and increases with age | Unknown – multifactorial; proposed link between diabetes mellitus type 2; possible AD inheritance | Frontoparietal hairline; eyebrows             | Topical/intralesional steroid treatments; doxycycline or minocycline; hydroxychloroquine; cyclosporine; mycophenolate mofetil; finasteride | Rule out TA if in ophiasis pattern; examine eyebrows; treatment considerations: Brimatoprost, tacrolimus, HT, PRP |
|             | FFA Prevalence unknown; <100 cases in the literature; may be misdiagnosed as TA | Variant of LPP                                                             | Thinning of crown and frontal scalp with frontal hairline preserved | Topical/intralesional steroid treatments; doxycycline or minocycline; hydroxychloroquine; cyclosporine; mycophenolate mofetil; finasteride | Can coexist with FPHL; may consider HT if stable on medical treatment for 1 year                     |

Abbreviations: ATN = acquired trichorrhexis nodosa; CCCA = central centrifugal cicatricial alopecia; FFA = frontal fibrosing alopecia; FPHL = female pattern hair loss; HT = hair transplantation; TA = traction alopecia; PRP = platelet rich plasma; AD = Autosomal Dominant.
Contraindications

Contraindications for hair transplantation are similar in all racial groups, and includes keloids scarring of which patients of color have a higher incidence. A careful and detailed history of keloid formation along with a physical examination to check for scars should be performed. Active disease with signs of inflammation or scarring alopecia, such as CCCA or FFA, is also a contraindication to hair transplantation. Disease must be quiescent on medical therapy for 9 to 12 months, and confirmed with biopsy test results before hair transplantation can be considered.

Complications

Most patients with Afro-textured hair have excellent results from hair transplantation surgery and low risk of keloidal scarring. Only one case of keloids at the donor site had been reported in a patient with no prior history of keloids (Brown et al., 1990) until 2017, when the first case of extensive keloid formation at the donor site in a patient after FUE was reported (Garg, 2017).

To avoid this complication, test grafting is recommended before a hair transplant procedure. The authors surmise that, if normal healing occurs in the donor area and recipient site after 3 months, the patient is a good candidate for a full hair transplant procedure. The risk of keloid formation can be reduced with the initiation of prompt postsurgical prophylactic techniques, including topical corticosteroid agents, silicone gel sheeting, pressure therapy, or onion extract-containing gel (Callender et al., 2005; Garg, 2017; Gauglitz, 2013; Lawson et al., 2017).

Platelet-rich plasma

PRP is a biological product that is defined as a portion of the plasma fraction of autologous blood with a platelet concentration above the baseline before centrifugation (Alves and Grimalt, 2016). As a result, PRP contains not only a concentrated amount of platelets, but also a robust complement of clotting factors, enriched by a range of growth factors that are thought to stimulate hair growth. Although not fully understood, the proposed mechanism of action of PRP is as follows: Activation of platelets via thrombin or calcium chloride ➔ Platelets undergo degranulation ➔ Growth factors are released ➔ Stimulate increased proliferation of dermal papilla cells via activation of extracellular-regulated kinase and Akt signaling ➔ Antiapoptotic effects (Li et al., 2012).

PRP utilizes autologous blood that is obtained by venipuncture in an anticoagulated tube (Alves and Grimalt, 2016). The blood is centrifuged with single- or double-spin centrifugation, depending on the device (Alves and Grimalt, 2016, 2018). The settings of the centrifuge set to obtain PRP at an adjustable concentration are defined by the manufacturer, and cannot be changed by the physician. After centrifugation, the tube shows three basic layers, and the middle layer corresponds with PRP. Thrombin and calcium chloride are used to activate platelets and stimulate degranulation, causing the release of growth factors (Table 3; Anitua et al., 2017). Some investigators activate platelets, but others utilize platelets without previously
activating them, postulating that doing so produces superior results (Alves and Grimalt, 2018). Currently, there is no consensus on the use of activators in PRP (Arshdeep and Kumaran, 2014).

The ideal volume to administer, the frequency of application, the exact site of administration, and which technique/preparation system to utilize remains highly controversial, and 12 distinct protocols are currently available. Alves and Grimalt (2018) report that PRP has demonstrated therapeutic effectiveness for androgenetic alopecia (AGA) in 10 of 12 studies, with 6 studies demonstrating a statistically significant improvement after treatment with PRP using objective measures, such as increased hair thickness and increased hair number (Dohan Ehrenfest et al., 2013; Lin et al., 2015; Mishra et al., 2012). Four additional studies showed hair improvement (e.g., hair density, diameter) with PRP, although no p-values or statistical analysis was described (Anitua et al., 2017; Arshdeep and Kumaran, 2014).

Although Alves and Grimalt (2018) suggest that PRP is a potential treatment option for AGA, the authors recognize that several limitations, such as lack of standardized treatment protocol for the application of PRP or standardized evaluation methods, need to be addressed to assess the efficacy of PRP on AGA before PRP can be broadly incorporated as a treatment option. The authors propose additional, large-scale, double-blind, randomized, controlled studies that treat both men and women, with standardized PRP preparation methods and administration protocols, repeated treatments, standardized objective data documentation and evaluation, physician and subject assessment, isolation of the effects of PRP in different grades of AGA, and performing long-term follow-up.

The authors also suggested protocols for PRP preparation that include a double-spin centrifugation method that consists of a first spin at 1500 to 1700 rpm for 6 to 10 minutes, followed by a second spin at 2500 rpm for 10 to 15 minutes (Alves and Grimalt, 2018). The use of an activator, preferably a Ca+2-containing compound such as calcium chloride or calcium gluconate, would activate platelets for the release of growth factors and cytokines, and likely provide better results. The recommended amount of total injected PRP is an average volume of 6.2 mL (range; 3–12 mL) of pure PRP. Intradermal injections should be made in selected scalp areas using the nappage technique (i.e., multiple small injections in a linear pattern 1 cm apart to a depth of 1.5–2.5 mm). The authors recommend a minimum of three sessions at 1-month intervals.

Finally, the authors recommended anesthesia, but we prefer the use of a cryogen cooler to achieve a numbing effect prior to the injection.

**Low-level laser therapy**

Although the first report on low-level light therapy addressed its stimulatory effect on hair growth in 1967, the significance of this beneficial action has been reevaluated in recent years. The basic biological mechanism of low-level light therapy on the molecular level is considered the absorption of red and near-infrared light by chromophores contained in the protein of components of the respiratory chain of mitochondria. In randomized, sham device-controlled, double-blind clinical trials conducted at multiple institutional and private practices, a total of 128 male and 141 female subjects were randomized to receive either a laser comb or sham device in concealed sealed packets, and treated on the entire scalp three times per week for 26 weeks (Jimenez et al., 2014). After 26 weeks, a statistically significant increase in terminal hair density was observed in subjects using the laser comb treatment compared with the sham device. The increase in terminal hair count was comparable with that of short-term trials of a 5% minoxidil topical solution and 1 mg/day of finasteride. A higher percentage of laser comb–treated subjects reported overall improvement of hair loss conditions and thickness and fullness of hair.

**Scalp micropigmentation**

A form of cosmetic tattooing called scalp micropigmentation is a less invasive, more permanent option to camouflage hair loss. The medical use of tattooing was described in 1998 for alopecia areata of the eyebrows (van der Velden et al., 1998). In 2001, Traquina reported that the use of micropigmentation on the scalp is a safe and effective technique to camouflage scalp scars (Traquina, 2001).

Standard cosmetic tattoo instruments are used with a skillful and artistic technique to deposit pigment through the skin in the upper dermis, creating dots between the pores on a balding scalp (Dhurat et al., 2017; Rassman et al., 2013). Typically, two to four sessions are required, with each session lasting up to 8 hours. Risks from the procedure include infection and allergies to the pigment. Disadvantages include greying of the hair over time that may appear mismatched from the scalp, and the need for touch-ups over time due to fading and progression of hair loss (Saed et al., 2017).

Park et al. (2014) performed micropigmentation in 43 Korean patients, including 23 female patients with FPHL, 14 male patients with male pattern baldness, and 6 patients with scalp scars. The results for 41 patients were highly satisfactory, and there were no adverse effects or complications. The results for one patient with FPHL Ludwig stage I were satisfactory per the physician's assessment. The patient was dissatisfied due to a lack of appreciable difference after the procedure. The procedural interventions for hair loss are summarized in Table 4.

**Conclusions**

Women of color suffer from various forms of hair loss. The etiology of many of these forms of alopecia is multifactorial, and has not been fully elucidated, which makes alopecia in this population difficult to treat. Early recognition of clinical signs of hair loss is critical to halt its progression. Treatment options include medical and surgical interventions with an individualized approach. Surgical correction, such as hair transplantation, remains a viable

| Growth factors | Main functions |
|----------------|----------------|
| PDGF           | Increases hair growth |
| Vascularization| Angiogenesis stimulator |
| TGF-β          | Inhibits hair growth in vitro |
| VEGF           | Hair-cell proliferation and regeneration |
| EGF            | Increases perifollicular angiogenesis during the anagen growth phase |
| HGF            | Angiogenesis stimulator |
| FGF            | Increases hair growth by inducing the anagen phase of HF |
| IGF            | Maintains HF growth in vitro |

**Abbreviations:** DP = differential pressure; EGF = epidermal growth factor; FGF = fibroblast growth factor; HF = hair follicle; HGF = hepatocyte growth factor; IGF = insulin-like growth factor; PDGF = platelet-derived growth factor; TGF-β = transforming growth factor beta; VEGF = vascular endothelial growth factor.

Source: Alves and Grimalt, 2016.
option for hair loss in women of color, even in those with scarring alopecia who have demonstrated stable disease confirmed by biopsy test results.

References

Aldoori N, Dobson K, Holden CR, McDonagh AJ, Harries M, Messenger AG. Frontal fibrosing alopecia: Possible association with leave-on facial skin care products and sunscreens; a questionnaire study. Br J Dermatol 2016;175(4):762–7.

Alves R, Grimalt R. Randomized placebo-controlled, double-blind, half-head study to assess the efficacy of platelet-rich plasma on the treatment of androgenetic alopecia. Dermatol Surg 2016;42(4):491–7.

Alves R, Grimalt R. A review of platelet-rich plasma; History, biology, mechanism of action, and classification. Skin Appendage Disord 2018;4(1):18–24.

Anitua E, Pino A, Martinez N, Orive G, Berridi D. The effect of the plasma rich in growth factors on pattern hair loss: A pilot study. Dermatol Surg 2017;43(5):658–70.

Arshdeep, Kumanar MS. Platelet-rich plasma in dermatology: Boon or a bane? Indian J Dermatol Venerol Leprol 2014;80(1):5–14.

Bolduc C, Sperling LC, Shapiro J. Primary cicatricial alopecia: Other lymphocytic pri-
cations. Clin Cosmet Investig Dermatol 2013;6:103–4.

Callender VD, Wright DR, Davis EC, Sperling LC. Hair breakage as a presenting sign of early or occult central centrifugal cicatricial alopecia: Clinicopathologic findings in 9 patients. Arch Dermatol 2012;148(9):1047–52.

Callender VD, Reid SD, Obayan O, McCallan L, Sperling L. Diagnostic clues to frontal fibrosing alopecia in patients of African descent. J Clin Aesthet Dermatol 2016;9(4):45–51.

Dini A, Okoye GA, Aguh C. Association of uterine leiomyomas with central centrifugal cicatricial alopecia. JAMA Dermatol 2016;154(2):213–4.

Dinh QQ, Sinclair R. Female pattern hair loss: Current treatment concepts. Clin Interv Aging 2007;2(2):185–99.

Dlova NC. Frontal fibrosing alopecia and lichen planus pigmentosus: Is there a link? Br J Dermatol 2013;168(2):439–42.

Dlova NC, Jordaen FH, Sarig O, Sprecher E. Autosomal dominant inheritance of central centrifugal cicatricial alopecia in black South Africans. J Am Acad Dermatol 2014;70(4):679–82 e1.

Dlova NC, Salkey KS, Callender VD, McMichael AJ. Central centrifugal cicatricial alopecia: New insights and a call for action. J Invest Dermatol 2017;138(2):554–6.

Ehrenfest DM, Sammartino G, Shibli J, Wang HL, Zou DR, Bernard JP. Guidelines for the publication of articles related to platelet concentrates (Platelet-Rich Plasma – PRP, or Platelet-Rich Fibrin – PRF): The international classification of the POSEIDO. POSEIDO 2013;1:17–27.

Garg S. Extensive donor site keloids in follicular unit extraction hair transplantation. Int J Trichol 2017;9(3):127–9.

Gathers RC, Jankowski M, Eide M, Lim HW. Hair grooming practices and central centrifugal cicatricial alopecia. J Am Acad Dermatol 2009;60(4):574–8.

Gauglitz G. Management of keloids and hypertrophic scars: Current and emerging options. Clin Cosmet Investig Dermatol 2013;6:103–14.

Harris JA. Follicular unit extraction. Facial Plast Surg Clin North Am 2013;21(3):375–84.
Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, Reichenberg JS. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): A systematic review. J Clin Aesthet Dermatol 2016;9(7):56–62.

International Society of Hair Restoration Surgery. Practice census facts and figures [Internet] 2017 Available from http://www.ishrs.org/statistics-research.htm, Accessed date: 14 June 2017.

Jimenez J, Wikramanayake T, Bergfeld W, Hordinsky M, Hickman J, Hamblin M, et al. Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: A multicenter, randomized, sham device-controlled, double-blind study. Am J Clin Dermatol 2014;15(2):115–27.

Khumalo NP, Ngwanya RM. Traction alopecia: 2% topical minoxidil shows promise. Report of two cases. J Eur Acad Dermatol Venereol 2007;21(3):433–4.

Kohler C, Tschumi K, Rodner C, Schneider M, Birkhaeuser M. Effect of finasteride 5 mg (Proscar) on acne and alopecia in female patients with normal serum levels of free testosterone. Gynecol Endocrinol 2007;23(3):142–5.

Kossard S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution. Arch Dermatol 1994;130:770–4.

Kyei A, Bergfeld WF, Piliang M, Summers P. Medical and environmental risk factors for the development of central centrifugal cicatricial alopecia: A population study. Arch Dermatol 2011;147(8):909–14.

Lawson CN, Hollinger J, Sethi S, Rodney I, Sarkar R, Dlova N, et al. Updates in the understanding and treatments of skin and hair disorders in women of color. Int J Women Dermatol 2015;1(2):59–75.

Lawson CN, Hollinger J, Sethi S, Rodney I, Sarkar R, Dlova N, et al. Updates in the understanding and treatments of skin & hair disorders in women of color. Int J Women Dermatol 2017;3(1 Suppl):S75.

Lawson CN, Hollinger J, Sethi S, Rodney I, Sarkar R, Dlova N, et al. Updates in the understanding and treatments of skin & hair disorders in women of color. Int J Women Dermatol 2018;57(1):104–9.

Lin W, Xiang LJ, Shi HK, Zhang J, Jiang L, Cai P, et al. Fibroblast growth factors stimulate hair growth through β-catenin and Shh expression in C57BL/6 mice. Biomed Res Int 2013(2013):730139.

Lichtenberg AJ. Hair and scalp disorders in ethnic populations. Dermatol Clin 2003;21(4):629–44.

Mishra A, Harmon K, Woodall, Vieira A. Sports medicine applications of platelet rich plasma. Curr Pharma Biotech 2012;13(7):1185–95.

Miteva M, Tosti A. Dermatoscopic features of central centrifugal cicatricial alopecia. J Am Acad Dermatol 2014;71(3):443–9.

Mukbi T, Rudnicka I, Olszewska M, Shapiro J. Evaluation and diagnosis of the hair loss patient. J Am Acad Dermatol 2014;71(3):415.e1–15.

Oliveira-Souza R, e Silva JD, Correia MP, Andrè MC. Finasteride 5 mg/day treatment of patterned hair loss in normo-androgenetic postmenopausal women. Int J Trichol 2013;5(1):22–5.

Olsen EA, Callender V, McMichael A, Sperling L, Anstrom KJ, Shapiro J, et al. Central hair loss in African American women: Incidence and potential risk factors. J Am Acad Dermatol 2011;64(2):245–52.

Park JH, et al. Micropigmentation: camouflaging scalp alopecia and scars in Korean patients. Aesth Plast Surg 2014;38:199–204.

Pierce H. The uniqueness of hair transplantation in black patients. J Natl Med Assoc 1976;68:343.

Rashid R. Follicular unit extraction with the Artas robotic hair transplant system system: An evaluation of FUE yield. Dermatol Online J 2014;20(4):22341.

Rassman WR, Bernstein RM, McClellan R, Jones R, Worton E, Uyttendaele H. Follicular unit extraction: Minimally invasive surgery for hair transplantation. Dermatol Surg 2002;28(8):720–8.

Rassman WR, Pak JP, Kim J. Scalp micropigmentation. Facial Plast Surg Clin North Am 2013;21(3):497–503.

Rogers NE, Callender VD. Advances and challenges in hair restoration of curly African-american hair. Dermatol Clin 2014;32(2):163–71.

Rose PT, Nusbaum B. Robotic hair restoration. Dermatol Clin 2014;32(1):97–107.

Saed S, Ibrahim O, Bergfeld WF. Hair camouflage: A comprehensive review. Int J Women Dermatol 2017;3(1 Suppl):S57–80.

Sinclair RD. Female pattern hair loss: A pilot study investigating combination therapy with low-dose oral minoxidil and spironolactone. Int J Dermatol 2018;57(1):104–9.

Singh MK, Avram MR. Technical considerations for follicular unit extraction in African-American hair. Dermatol Surg 2013;39(8):1282–4.

Taylor SC, Kelly AP, Lim H, Serrano AMA. Taylor and Kelly’s dermatology for skin of color. 2nd ed.New York, NY: McGraw-Hill Education/Medical; 2016.

Taylor SC, Barbosa V, Burgess C, Heath C, McMichael AJ, Ogunleye T, et al. Hair and scalp disorders in adult and pediatric patients with skin of color. Cutis 2017;100(1):31–5.

Traquina AC. Micropigmentation as an adjuvant in cosmetic surgery of the scalp. Dermatol Surg 2001;27(2):123–8.

Umar S. Comparative study of a novel tool for follicular unit extraction for individuals with Afro-textured hair. Plastic Reconstr Surg 2016;137(4):e1069.

Uwakwe L, Cardwell L, Dothard E, Baroudi B, McMichael A. Frontal hair loss in African American women: Incidence and potential risk factors. J Am Acad Dermatol 2011;64(2):245–52.